Compare · AXDX vs RVTY
AXDX vs RVTY
Side-by-side comparison of Accelerate Diagnostics Inc. (AXDX) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXDX and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $11.33B, about 57.4x AXDX ($197.2M).
- RVTY has hit the wire 2 times in the past 4 weeks while AXDX has been quiet.
- RVTY has more recent analyst coverage (19 ratings vs 1 for AXDX).
- Company
- Accelerate Diagnostics Inc.
- Revvity Inc.
- Price
- $0.14+59.82%
- $101.42+0.00%
- Market cap
- $197.2M
- $11.33B
- 1M return
- -
- +2.09%
- 1Y return
- -
- +5.98%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 2
- Recent ratings
- 1
- 19
Accelerate Diagnostics Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Latest AXDX
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- SEC Form NT 10-Q filed by Accelerate Diagnostics Inc.
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
- SEC Form 3 filed by new insider Shalhoub Paul Vincent
- Amendment: SEC Form 10-K/A filed by Accelerate Diagnostics Inc.
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update
- Chief Executive Officer Phillips Jack converted options into 53,283 shares and sold $16,473 worth of shares (25,343 units at $0.65), increasing direct ownership by 17% to 191,374 units (SEC Form 4)
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)